DNA based neoepitope vaccination induces tumor control in syngeneic mouse models

Recent findings have positioned tumor mutation-derived neoepitopes as attractive targets for cancer immunotherapy. Cancer vaccines that deliver neoepitopes via various vaccine formulations have demonstrated promising preliminary results in patients and animal models. In the presented work, we assess...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2023-05, Vol.8 (1), p.77-77, Article 77
Main Authors: Viborg, Nadia, Pavlidis, Michail Angelos, Barrio-Calvo, Marina, Friis, Stine, Trolle, Thomas, Sørensen, Anders Bundgaard, Thygesen, Christian Bahne, Kofoed, Søren Vester, Kleine-Kohlbrecher, Daniela, Hadrup, Sine Reker, Rønø, Birgitte
Format: Article
Language:English
Subjects:
631/250/580/1884
631/250/590/1991
631/67/580/1884
Animal models
Antigens
Biomedical and Life Sciences
Biomedicine
Cancer
Clinical trials
Cytokines
Deoxyribonucleic acid
DNA
Immunization
Immunogenicity
Immunotherapy
Infectious Diseases
Lymphocytes
Medical Microbiology
Medical prognosis
Mutation
Public Health
Rodents
Tumors
Vaccine
Vaccines
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent findings have positioned tumor mutation-derived neoepitopes as attractive targets for cancer immunotherapy. Cancer vaccines that deliver neoepitopes via various vaccine formulations have demonstrated promising preliminary results in patients and animal models. In the presented work, we assessed the ability of plasmid DNA to confer neoepitope immunogenicity and anti-tumor effect in two murine syngeneic cancer models. We demonstrated that neoepitope DNA vaccination led to anti-tumor immunity in the CT26 and B16F10 tumor models, with the long-lasting presence of neoepitope-specific T-cell responses in blood, spleen, and tumors after immunization. We further observed that engagement of both the CD4+ and CD8+ T cell compartments was essential to hamper tumor growth. Additionally, combination therapy with immune checkpoint inhibition provided an additive effect, superior to either monotherapy. DNA vaccination offers a versatile platform that allows the encoding of multiple neoepitopes in a single formulation and is thus a feasible strategy for personalized immunotherapy via neoepitope vaccination.
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-023-00671-5